This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
-
Seaport Investigator Site, Chino, California, United States, 91710
Seaport Investigator Site, West Palm Beach, Florida, United States, 33407
Seaport Investigator Site, Atlanta, Georgia, United States, 30328
Seaport Investigator Site, Saint Louis, Missouri, United States, 63141
Seaport Investigator Site, Brooklyn, New York, United States, 11235
Seaport Investigator Site, Staten Island, New York, United States, 10314
Seaport Investigator Site, North Canton, Ohio, United States, 44720
Seaport Investigator Site, Irving, Texas, United States, 75062
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
Seaport Therapeutics,
David Walling, Ph.D., PRINCIPAL_INVESTIGATOR, Collaborative Neuroscience Research - Garden Grove
2027-03